Trade Names:Caduet- Tablets 5 mg amlodipine per 10 mg atorvastatin- Tablets 5 mg amlodipine per 20 mg atorvastatin- Tablets 5 mg amlodipine per 40 mg atorvastatin- Tablets 5 mg amlodipine per 80 mg atorvastatin- Tablets 10 mg amlodipine per 10 mg atorvastatin- Tablets 10 mg amlodipine per 20 mg atorvastatin- Tablets 10 mg amlodipine per 40 mg atorvastatin- Tablets 10 mg amlodipine per 80 mg atorvastatin
Inhibits movement of calcium ions across cell membrane in systemic and coronary vascular smooth muscle.Atorvastatin
Increases rate at which body removes cholesterol from blood and reduces production of cholesterol in body by inhibiting enzyme that catalyzes early rate-limiting step in cholesterol synthesis; increases HDL; reduces LDL, VLDL, and triglycerides (TG).
Treatment of hypertension; chronic stable angina; confirmed or suspected vasospastic angina (Prinzmetal or Variant angina).Atorvastatin
As an adjunct to diet to reduce elevated total cholesterol (C), LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia; adjunct to diet for treatment of elevated serum TG levels (Fredrickson Type IV); treatment of primary dysbetalipoproteinemia (Fredrickson Type III); reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia, and apo B levels in boys and postmenarchal girls, 10 to 17 yr of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following are present: LDL-C remains at 190 mg/dL or higher; LDL-C remains at 160 mg/dL or higher and there is positive family history of premature cardiovascular disease (CVD) or 2 or more CVD risk factors are present in children.
Active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding mothers hypersensitivity to any component of the product.
Dosage must be individualized based on effectiveness and tolerance for each individual component in the treatment of hypertension/angina and hyperlipidemia. Amlodipine/Atorvastatin may be substituted for its individually titrated components. Patients may be given the equivalent dose of amlodipine/atorvastatin or a dose of amlodipine/atorvastatin with increased amounts of amlodipine, atorvastatin, or both for additional antianginal effects, BP lowering, or lipid-lowering effect. As initial therapy for one indication and continuation of treatment of the other, select the recommended starting dose of amlodipine/atorvastatin based on the continuation of the component being used and the recommended starting dose of the added monotherapy. The max dose of amlodipine component is 10 mg once daily; the max dose of atorvastatin component is 80 mg daily.
Administer alone or in combination with other lipid-lowering therapy (eg, bile acid sequestrant) or with other cardiovascular medications for the treatment of hypertension and angina.
Store tablets at controlled room temperature (59° to 86°F).
Atorvastatin plasma concentrations may be decreased.Digoxin, oral contraceptives (eg, ethinyl estradiol, norethindrone)
Plasma concentrations of these agents may be elevated by atorvastatin, increasing the risk of side effects.Erythromycin
Atorvastatin plasma concentrations may be increased, increasing the pharmacologic and adverse reactions.
None well documented.
Palpitation (5%); vasodilation, syncope, migraine, postural hypotension, phlebitis, arrhythmia, angina pectoris, hypertension (less than 2%).
Fatigue (5%); dizziness (3%); somnolence (2%).Atorvastatin
Headache (17%); asthenia (4%); insomnia, dizziness (more than 2%); paresthesia, somnolence, amnesia, abnormal dreams, decreased libido, emotional lability, incoordination, peripheral neuropathy, torticollis, facial paralysis, hyperkinesia, depression, hypesthesia, hypertonia (less than 2%).
Rash (4%); photosensitivity, pruritus, contact dermatitis, alopecia, dry skin, sweating, acne, urticaria, eczema, seborrhea, skin ulcer (less than 2%); bullous rash including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (postmarketing).
Rhinitis (less than 2%).Atorvastatin
Amblyopia, tinnitus, dry eyes, refraction disorder, eye hemorrhage, deafness, glaucoma, parosmia, taste loss, taste perversion (less than 2%).
Nausea (3%); abdominal pain (2%).Atorvastatin
Abdominal pain, diarrhea, dyspepsia (4%); constipation, flatulence (3%); nausea (more than 2%); gastroenteritis, colitis, vomiting, gastritis, dry mouth, rectal hemorrhage, esophagitis, eructation, glossitis, mouth ulceration, anorexia, increased appetite, stomatitis, biliary pain, cheilitis, duodenal ulcer, dysphagia, enteritis, melena, gum hemorrhage, stomach ulcer, tenesmus, ulcerative stomatitis, pancreatitis, (less than 2%).
UTI (more than 2%); urinary frequency, cystitis, hematuria, impotence, dysuria, kidney calculus, nocturia, epididymitis, fibrocystic breast, vaginal hemorrhage, albuminuria, breast enlargement, metrorrhagia, nephritis, urinary incontinence, urinary retention, urinary urgency, abnormal ejaculation, uterine hemorrhage (less than 2%).
Ecchymosis, anemia, lymphadenopathy, thrombocytopenia, petechiae (less than 2%).
Jaundice, hepatic enzyme elevations (postmarketing).Atorvastatin
Abnormal LFTs, hepatitis, cholestatic jaundice (less than 2%).
Peripheral edema (more than 2%); hyperglycemia, increased creatine phosphokinase, gout, weight gain, hypoglycemia (less than 2%).
Arthralgia (5%); back pain (4%); myalgia (3%); arthritis (more than 2%); leg cramps, bursitis, tenosynovitis, myasthenia, tendinous contracture, myositis (less than 2%); rhabdomyolysis (postmarketing).
Sinusitis (6%); pharyngitis (3%); bronchitis (more than 2%); pneumonia, dyspnea, asthma, epistaxis (less than 2%).
Edema (15%); flushing (5%).Atorvastatin
Infection (10%); accidental injury (4%); flu syndrome, allergic reaction (3%); chest pain (at least 2%); face edema, fever, malaise (less than 2%); angioneurotic edema (postmarketing).
If muscle pain, tenderness, and/or weakness develop during therapy, determine CPK levels. Notify health care provider if CPK levels are markedly increased or if muscle symptoms continue or worsen, or are accompanied by malaise or fever.LFTs
Ensure LFTs (transaminases) are determined before and 12 wk following initiation of therapy, or after increase in dose of atorvastatin, and periodically thereafter (eg, every 6 mo).Serum cholesterol/Triglycerides
Ensure serum cholesterol and triglycerides are measured before therapy is started and within 2 to 4 wk of starting therapy or changing the atorvastatin dose, and then periodically thereafter.Serum transaminase levels
If elevated serum transaminase levels develop during treatment, repeat levels more frequently. If transaminase levels rise to 3 times upper limit of normal and persist, notify health care provider. Be prepared to reduce dose or discontinue therapy if ordered.
Category X .
Undetermined (see contraindications).
Safety and efficacy not established for treating hypertension in patients under 6 yr of age.Atorvastatin
Safety and efficacy not established for pre-pubertal patients or patients younger than 10 yr of age.
Rarely, patients have developed increased frequency, duration and severity of angina, or acute MI on starting or increasing the dose of calcium channel blocker therapy.
Use amlodipine with caution.
Ensure secondary causes of hypercholesterolemia (eg, poorly controlled diabetes, hypothyroidism) are excluded before starting therapy.
HMG-CoA reductase inhibitors have been associated with biochemical abnormalities of liver function.
Ensure therapy is temporarily withheld in patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension).
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported.
Might be expected to cause excessive peripheral vasodilation with marked hypotension and possible reflex tachycardia.
Copyright © 2009 Wolters Kluwer Health.